Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intas Pharma

- PMLiVE

Endo buys Par for $8bn as M&A mania marches on

Acquisitionwill make Endo the fifth largest generics company in the US

Teva Pharma logo

Teva says chronic migraine drug is ready for phase III

TEV-48125 efficacy “has not previously been achieved”

Pharma deals in April 2015

The love affair with oncology continues, finds Medius Deal Watch

Medius Deal Watch table for April 2015

The top major pharma mergers, acquisitions and collaborations during the month continued pharma's love affair with oncology

Pharma deals in March 2015

AbbVie's Pharmacyclics mega-merger dominated the month, finds Medius Deal Watch

Medius Deal Watch table for March 2015

The top major pharma mergers, acquisitions and collaborations during the month were dominated by AbbVie's Pharmacyclics mega-merger

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

- PMLiVE

Perrigo rejects Mylan again as Teva bites back

There is much debate over the value of the company’s shares

Bristol-Myers Squibb (BMS) building

BMS shines in Q1, but Abilify generics cast a long shadow

Revenue up 6% but Ablify’s contribution likely to drop due to competition

- PMLiVE

Mylan pulls no punches in rejecting Teva takeover

Firm calls Israeli generics giant’s credibility into question

Pharma deals in February 2015

Pfizer and Valeant led the way during a respectable, if not record-breaking, month for mergers, acquisitions and collaborations

Medius Deal Watch table for February 2015

The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links